Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Spruce Biosciences (SPRB) “announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...

Acelyrin (SLRN) announced that its Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a ...